As per NPPA Order S.O. 5690(E) dated 17 October 2026, the trade margin on 137 non-scheduled anti-cancer medicines is capped at 30%. Hetero’s revised MRPs take effect on 9 November 2026.
Patients and partners with questions about the revised prices are welcome to speak to their doctor, pharmacist or hospital.
Source: NPPA Order S.O. 5690(E), The Gazette of India, 17 October 2026.
The KRIS Division of Hetero Healthcare focuses on cardiovascular and metabolic healthcare, offering therapeutic solutions for the long-term management of chronic conditions.
Its portfolio addresses key areas such as hypertension, dyslipidaemia, cardiovascular risk management, diabetes, and associated metabolic disorders, supporting comprehensive cardiometabolic care.
Backed by Hetero Healthcare’s commitment to quality, accessibility, and patient-centric care, KRIS strives to provide dependable therapies that support effective disease management and better patient outcomes.
View by-
